Eculizumab dosing in infants

Abstract

Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in infants, and for smaller vials of the medication to facilitate more precise dosing. Such changes would ensure that adverse events are minimized and that the children with aHUS who are treated with eculizumab experience an optimal clinical response.

Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome

“…C) Eculizumab is a humanized anti-C5 monoclonal antibody that prevents the formation of the membrane attack complex by binding to human C5 with high affinity and preventing its cleavage by complement conversion into C5a and C5b (inhibition of terminal complement activity). 7 , 8 . This medication induces both hematological and renal remission especially if it is started early (less than 7 days).…”

Resolution of MoS2 Nanosheets‐Induced Pulmonary Inflammation Driven by Nanoscale Intracellular Transformation and Extracellular‐Vesicle Shuttles

“…[18][19][20][21] Heavy metals and particularly molybdenum exposure has been related to health hazards such as fetal growth disturbance, [22] systemic sclerosis, [23] or chronic kidney disease. [24] Depending on the form of TMD and the exfoliation degrees, in vitro studies demonstrated different levels of cytotoxicity. [25,26] Additionally, differences in the antibacterial activity were observed between exfoliated MoS 2 and annealed MoS 2 in combination with ethylenediaminetetraacetic acid as an electron donor.…”